NASDAQ · TRDA
Healthcare · Biotechnology
$5.48
Down-$0.06 (-1.09%)
Updated Oct 6, 2026, 10:38 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · TRDA
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
TRDA closed at $5.48 after 20 trading sessions, down 27.13% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $5.38 | $5.48 | $5.15 | $5.48 | 463.81K |
| Oct 2, 2026 | $5.77 | $6.22 | $5.1701 | $5.38 | 463.71K |
| Oct 1, 2026 | $6.32 | $6.36 | $5.6001 | $5.68 | 425.14K |
| Sep 30, 2026 | $6.20 | $6.39 | $6.125 | $6.35 | 239.86K |
| Sep 29, 2026 | $6.25 | $6.43 | $6.08 | $6.26 | 268.59K |
| Sep 28, 2026 | $6.13 | $6.24 | $5.925 | $6.22 | 442.59K |
| Sep 25, 2026 | $6.23 | $6.245 | $6.01 | $6.16 | 374.04K |
| Sep 24, 2026 | $6.47 | $6.47 | $6.14 | $6.22 | 319.12K |
| Sep 23, 2026 | $6.71 | $6.71 | $6.37 | $6.50 | 282.77K |
| Sep 22, 2026 | $6.71 | $6.9299 | $6.654 | $6.71 | 195.52K |
| Sep 21, 2026 | $6.81 | $6.81 | $6.455 | $6.64 | 375.3K |
| Sep 18, 2026 | $6.85 | $6.89 | $6.60 | $6.75 | 354.43K |
| Sep 17, 2026 | $6.91 | $7.05 | $6.665 | $6.90 | 297.36K |
| Sep 16, 2026 | $6.92 | $6.99 | $6.74 | $6.89 | 249.22K |
| Sep 15, 2026 | $7.05 | $7.05 | $6.67 | $6.88 | 247.77K |
| Sep 14, 2026 | $6.80 | $7.07 | $6.72 | $7.05 | 336.1K |
| Sep 11, 2026 | $6.49 | $6.81 | $6.29 | $6.80 | 291.81K |
| Sep 10, 2026 | $7.00 | $7.175 | $6.38 | $6.42 | 448.06K |
| Sep 9, 2026 | $7.47 | $7.55 | $7.02 | $7.11 | 382.04K |
| Sep 8, 2026 | $7.02 | $7.70 | $6.945 | $7.52 | 514.21K |
The latest Smart Investors Daily articles mentioning TRDA.
Company
Market Activity
Research & News
TRDA research
Company profile and research snapshot.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 8, 2026 | Guggenheim | Buy | — |
| May 8, 2026 | HC Wainwright & Co. | Neutral | — |
| Apr 6, 2026 | Oppenheimer | Outperform | — |
| Feb 18, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 11, 2026 | Guggenheim | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 24, 2026
Wall Street loves a good upgrade, especially when the stock has already doubled and the analyst can explain why everyone should have owned it six months ago. One place I look for ideas is the investment portfolios of
Yahoo · Sep 10, 2026
-- Announced following World Duchenne Awareness Day on September 7, grants are designed to support projects bridging healthcare disparities across the global Duchenne community -- BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the recipients of its 2026 DREAMS Grant Program: a competitive annual program that awards two $50,000 grants in support of projects working to better identify, understand and reach members of the Duchenne muscular dystr
Yahoo · Sep 2, 2026
BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 61,365 restricted stock units (“RSUs”) and options to purchase 19,425 shares of the Company’s common stock to eight newly-hired non-executive employees under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of September 1, 2026. The options have an exercise price of $7.07 per share, which is equal to the closing price of the
Yahoo · Aug 5, 2026
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of +12.93% and +2.05%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TRDA.
